This year-in-review addresses developments in securities class actions brought against life sciences companies in 2018. We begin with an overview and analysis of trends in decisions involving life sciences companies with products at two distinct stages of development— pre- and post-FDA approval. We then provide summaries of the 55 federal district court and appellate court decisions surveyed. Finally, we catalog the new securities class action complaints filed against life sciences companies in 2018.
- Checklist Checklist: Pre-appointment checks to consider when selecting an appointed representative (UK) Recently updated
- How-to guide How-to guide: The appointed representatives regime explained - what it means in practice (UK) Recently updated
- Checklist Checklist: Preparing an application to the FCA or the PRA for a Part 4A permission (UK)